Last reviewed · How we verify
DPK-060
DPK-060 is a topical treatment that modulates the immune response to reduce inflammation.
DPK-060 is a topical treatment that modulates the immune response to reduce inflammation. Used for Moderate to severe plaque psoriasis, Atopic dermatitis.
At a glance
| Generic name | DPK-060 |
|---|---|
| Sponsor | DermaGen AB |
| Drug class | Immunomodulator |
| Target | IL-17 receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
DPK-060 works by targeting a specific pathway involved in the development of inflammatory skin conditions. This leads to a reduction in inflammation and improvement in symptoms. Further research is needed to fully understand its mechanism of action.
Approved indications
- Moderate to severe plaque psoriasis
- Atopic dermatitis
Common side effects
- Skin irritation
- Headache
- Nausea
Key clinical trials
- A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060 (PHASE1, PHASE2)
- A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPK-060 CI brief — competitive landscape report
- DPK-060 updates RSS · CI watch RSS
- DermaGen AB portfolio CI